Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.
Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.
Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion Criteria:
Exclusion Criteria:
celine.im@abbvie.com+82-10-2230-3629
Daejeon, Daejeon Gwang Yeogsi 35015, South Korea
Gangwon-do, Gang Weondo 24253, South Korea
Gwangju, Gwangju Gwang Yeogsi 61469, South Korea
Goyang-si, Gyeonggido 10444, South Korea
Hwaseong, Gyeonggido 18450, South Korea
Hwaseong, Gyeonggido 18450, South Korea
Seongnam-si, Gyeonggido 13620, South Korea
Uijeongbu-si, Gyeonggido 11759, South Korea
Daegu, Gyeongsangbuk-do 42472, South Korea
Daegu, Gyeongsangbuk-do 42601, South Korea
Changwon-si, Gyeongsangnam-do 51394, South Korea
Incheon, Incheon Gwang Yeogsi 21431, South Korea
Seoul, Seoul Teugbyeolsi 01830, South Korea
Seoul, Seoul Teugbyeolsi 03722, South Korea
Seoul, Seoul Teugbyeolsi 07985, South Korea